Partnerships

Working with patients in mind

We are developing new treatments for conditions like depression and alcohol use disorder, and we work closely with people from across the mental health ecosystem to push forward research, inform our clinical development and support clinical trial participants.

We know that psychedelic-based treatments can bring about powerful experiences. That is why we are committed not just to innovation, but to listening, learning and acting on the insights of those with experience of living with mental health conditions and taking part in psychedelic clinical studies. Their perspectives inform everything we do, from how we design our studies to how we support participants before, during and after treatment.

Clinical research guided by experience

We are working to develop effective, rapid-acting and convenient new treatment options for people living with difficult-to-treat mental health conditions. We are deeply grateful to the 250+ participants who have already contributed to our research via clinical trials. Their involvement has been vital to advancing understanding of our investigational compounds and the patient experience.

Understanding the patient experience

As part of our BPL-003 studies, we have been closely monitoring how people subjectively experience treatment with the compound in a clinical setting in order to better characterise the participant experience. These insights have informed how we prepare, support and care for participants before, during and after treatment.

We are also supporting a PhD project that looks at how people process and integrate their experiences with BPL-003. Through interviews and surveys, this research will help us understand how change happens after treatment with BPL-003 and will help us refine our trial and training protocols for future studies.

Our Clinical Trials

Partnering with Patients

We believe that people with lived experience of mental health conditions and of participating in psychedelic clinical trials are essential partners in shaping the next generation of mental health treatments. Their insights help us to continuously improve and stay grounded in what truly matters.

Patient Council

In 2023, we created a Patient Council in partnership with The Psychedelic Participant Advocacy Network (PsyPAN). The Council included 4 patient experts with personal experience of living with mental health conditions and taking part in psychedelic clinical trials, along with 3 members of Beckley Psytech’s team who specialise in patient support and trial design.

Over a year, the Council held 3 workshops focused on the full trial journey - from signing up and preparing for treatment, to the experience itself and integration. Together, we identified areas where improvements could be made and developed suggestions to help others in the field. These insights were shared in a Patient Impact Report.

In recognition of the Patient Council project, and the collaboration between Beckley Psytech and PsyPAN, Beckley Psytech received the Silver Standard in OVID Health's 2024 Patient Partnership Index (PPI) in 2023 and 2024.

“Not only will the Patient Council help form best practices, the aim is that these insights and this knowledge will be shared for the benefit of the whole psychedelic-assisted therapy ecosystem. This is exactly the kind of connected thinking we need to ensure participant safety and wellbeing and to maximise the potential of these treatments.”

Ian Roullier
PsyPAN co-founder

Read the Impact Report

Post-Participant Peer Support Pilot

We have provided PsyPAN with funding for a peer support program. The 12-month pilot is currently available to 20 UK-based participants who have taken part in a UK-based psychedelic clinical trial for a serious mental health illness.

If you would like to take part, please email PsyPAN on peersupport@psypanglobal.org to register your interest.

Advocacy and Community Engagement

We are committed to working with partners to shape policies that support fair access to innovative and effective mental health treatments. By working together, we believe we can drive more inclusive and impactful mental health solutions from research through to reality.

Mental Health America

In 2025, we joined Mental Health America’s Regional Policy Council - a national network dedicated to shaping mental health policy through community, collaboration, and lived experience. This partnership reflects our belief that meaningful progress in mental health care depends on listening to those with lived experience and working together to ensure that innovation translates into real-world impact. Through the Council, we hope to contribute to policy conversations that support thoughtful, equitable access to emerging treatments.

You are leaving Beckley Psytech